<- Go Home
Liminatus Pharma, Inc.
Liminatus Pharma, Inc. operates as a pre-clinical stage biopharmaceutical company that develops novel cancer therapies. It is developing CD47, a high affinity humanized anti CD47 antibody that has the potential to translate into clinic for CD47 SIRPa blocking and restoring the anti-tumor function of innate immune cells without inducing hemagglutination or hemolysis. The company was founded in 2018 is based in LA Palma, California.
Market Cap
$31.7M
Volume
161.2K
Cash and Equivalents
$1.3M
EBITDA
N/A
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
N/A
Profit Margin
N/A
52 Week High
$33.66
52 Week Low
$1.11
Dividend
N/A
Price / Book Value
-3.46
Price / Earnings
-127.27
Price / Tangible Book Value
-3.46
Enterprise Value
$31.8M
Enterprise Value / EBITDA
N/A
Operating Income
-$2.1M
Return on Equity
N/A
Return on Assets
N/A
Cash and Short Term Investments
$1.3M
Debt
$1.4M
Equity
-$8.8M
Revenue
N/A
Unlevered FCF
N/A
Sector
Biotechnology
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium